Incretin Atlas › Molecules › DR10624
DR10624
GLP-1/GCG/FGF21 · s.c. · Doer Biologics
Summary
- Also known as
- Zhejiang Doer Biologics
- Mechanism
- GLP-1/GCG/FGF21
- Route
- s.c.
- Company
- Doer Biologics
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 in severe hypertriglyceridaemia; obesity/MASH in development verify
- Next milestone
- Phase 3 readout (sHTG)
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 0 no data | ||
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 1 phase 2 / signal | Phase 2 only | |
| HFpEF | 0 no data | ||
| MASH | 1 phase 2 / signal | Phase 2 only | |
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Registered trials (5)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07848880 A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease | CKD | Phase 2 | not yet recruiting | 2026-10 → 2028-04 | 315 | not yet recruiting | NCT07848880 |
| NCT07680829 A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia | Other | Phase 3 | not yet recruiting | 2026-08 → 2030-06 | 378 | not yet recruiting | NCT07680829 |
| NCT07693777 A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | Other | Phase 3 | not yet recruiting | 2026-08 → 2029-02 | 480 | not yet recruiting | NCT07693777 |
| NCT07024212 Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects | MASH | Phase 2 | active not recruiting | 2025-04 → 2026-06 | 110 | active not recruiting | NCT07024212 |
| NCT06555640 A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | Other | Phase 2 | completed | 2024-08 → 2025-06 | 79 | Completed; results not in the atlas yet | NCT06555640 |
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: DR10624. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/dr10624/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.